![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Harari, Sergio; Wells, Athol U.; Wuyts, Wim A.; Nathan, Steven D.; Kirchgaessler, Klaus-Uwe; Bengus, Monica und Behr, Juergen
(2022):
The 6-min walk test as a primary end-point in interstitial lung disease.
In: European Respiratory Review, Bd. 31, Nr. 165, 220087
Behr, Jürgen; Nathan, Steven D.; Wuyts, Wim A.; Bishop, Nesrin Mogulkoc; Bouros, Demosthenes E.; Antoniou, Katerina; Guiot, Julien; Kramer, Mordechai R.; Kirchgaessler, Klaus-Uwe; Bengus, Monica; Gilberg, Frank; Perjesi, Andras; Harari, Sergio und Wells, Athol U.
(2021):
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
In: Lancet Respiratory Medicine, Bd. 9, Nr. 1: S. 85-95
Nathan, Steven D.; Costabel, Ulrich; Albera, Carlo; Behr, Jürgen; Wuyts, Wim A.; Kirchgaessler, Klaus-Uwe; Stauffer, John L.; Morgenthien, Elizabeth; Chou, Willis; Limb, Susan L. und Noble, Paul W.
(2019):
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
In: Respiratory Medicine, Bd. 153: S. 44-51
Behr, Jürgen; Nathan, Steven D.; Harari, Sergio; Wuyts, Wim; Kirchgaessler, Klaus-Uwe; Bengus, Monica; Gilberg, Frank und Wells, Athol U.
(2018):
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
In: Respiratory Medicine, Bd. 138: S. 13-20